Interaction of neutrophil counts and folic acid treatment on new-onset proteinuria in hypertensive patients.

Interaction of neutrophil counts and folic acid treatment on new-onset proteinuria in hypertensive patients. Br J Nutr. 2020 Dec 14;:1-25 Authors: Zhang Z, Liu M, Zhang Y, Zhou C, He P, Li H, Li J, Zhang Y, Liang M, Wang B, Xu X, Wang X, Huo Y, Hou FF, Nie J, Xu X, Qin X Abstract We aimed to examine whether baseline neutrophil counts affected the risk of new-onset proteinuria in hypertensive patients, and, if so, whether folic acid treatment is particularly effective in proteinuria prevention in such a setting. A total of 8,208 eligible participants without proteinuria at baseline were analyzed from the renal sub-study of the China Stroke Primary Prevention Trial (CSPPT). Participants were randomized to receive a double-blind daily treatment of 10mg enalapril and 0.8mg folic acid (n=4,101) or 10mg enalapril alone (n=4,107). The primary outcome was new-onset proteinuria, defined as a urine dipstick reading of ≥1+ at the exit visit. The mean age of the participants was 59.5 (SD, 7.4) years, 3,088 (37.6%) of the participants were male. The median treatment duration was 4.4 years. In the enalapril-alone group, a significantly higher risk of new-onset proteinuria was found among participants with higher neutrophil counts (quintile 5; ≥4.8×109/L, OR, 1.44; 95%CI: 1.00, 2.06), compared with those in quintile 1-4. For those with enalapril and folic acid treatment, compared with the enalapril-alone, the new-onset proteinuria risk was red...
Source: The British Journal of Nutrition - Category: Nutrition Authors: Tags: Br J Nutr Source Type: research